Federated Hermes Inc. Cuts Stake in Omnicell, Inc. $OMCL

Federated Hermes Inc. reduced its position in Omnicell, Inc. (NASDAQ:OMCL) by 11.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 525,439 shares of the company’s stock after selling 69,505 shares during the quarter. Federated Hermes Inc.’s holdings in Omnicell were worth $16,000,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. WINTON GROUP Ltd bought a new stake in Omnicell during the second quarter valued at about $2,692,000. State of Alaska Department of Revenue lifted its position in shares of Omnicell by 8.7% during the second quarter. State of Alaska Department of Revenue now owns 27,906 shares of the company’s stock valued at $819,000 after buying an additional 2,242 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Omnicell by 1.3% in the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock valued at $41,854,000 after buying an additional 17,680 shares in the last quarter. Advantage Alpha Capital Partners LP purchased a new position in shares of Omnicell in the 2nd quarter worth approximately $2,476,000. Finally, Assenagon Asset Management S.A. raised its stake in shares of Omnicell by 1,316.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 140,675 shares of the company’s stock worth $4,284,000 after acquiring an additional 130,742 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on OMCL shares. UBS Group set a $53.00 target price on shares of Omnicell in a research note on Friday, January 16th. Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 9th. Wells Fargo & Company boosted their target price on Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. KeyCorp upgraded Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target for the company in a research note on Wednesday, January 7th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Omnicell in a research note on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $48.57.

Insiders Place Their Bets

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the transaction, the executive vice president directly owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 2.52% of the company’s stock.

Omnicell Stock Down 1.2%

Shares of OMCL stock opened at $48.50 on Friday. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.00. The firm has a market capitalization of $2.18 billion, a PE ratio of 112.79, a P/E/G ratio of 5.23 and a beta of 0.77. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.21 and a current ratio of 1.44. The stock’s 50-day simple moving average is $45.53 and its 200-day simple moving average is $36.49.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.